- SD Biosensor Inc (SDB) and SJL Partners LLC have agreed to acquire Meridian Bioscience Inc (NASDAQ:VIVO) in an all-cash transaction valued at approximately $1.53 billion.
- Under the terms of the agreement, Meridian shareholders will receive $34.00 per share in cash, representing a premium of approximately 32% over the last close price before the Consortium’s first offer on March 18.
- The transaction is expected to close in the fourth calendar quarter of 2022.
- Upon completion of the transaction, SDB will own 60%, and SJL will own 40% of Meridian, which will no longer be traded or listed on any public securities exchange.
- Separately, Meridian Bioscience provided interim Q3 FY22 sales of $66 million – $69 million, against the consensus of $69.57 million.
- The company expects the Diagnostics segment’s sales to be $41 million – $43 million and the Life Science segment’s sales to be $25 million – $26 million.
- Price Action: VIVO shares are down 1.00% at $33.22 on the last check Thursday.
Ocular Therapeutix Announced Interim 7-month Data from U.S. Phase 1 Clinical Trial of OTX-TKI for the Treatment of Wet AMD; Said 80% of Subjects were Rescue-Free up to 6 months and 73% of Subjects Were Rescue-Free up to 7 months Following a Single OTX-…
Ocular Therapeutix, Inc. (NASDAQ: OCUL) today announced interim 7-month data from its U.S. Phase 1 clinical trial evaluating OTX-TKI, the Company's axitinib intravitreal hydrogel implant being developed for the treatment of wet age-related macular degeneration (wet AMD) and other retinal diseases.
